2型糖尿病患者踝臂指数与颈动脉粥样硬化的相关性

Correlation of Ankle Brachial Index and Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus

目的研究2型糖尿病患者踝臂指数(ABI)与颈动脉粥样硬化的相关性。方法随机选取2018年1月至2020年12月就诊于我科门诊和病房的693例2型糖尿病患者作为本次研究对象,收集性别、年龄、病程等相关临床资料。以ABI=0.9为界值分组:ABI<0.9为甲组,ABI≥0.9为乙组,检查两组患者的颈动脉内膜中层厚度(IMT)、斑块有无、血管内径等超声检测参数,并进行相关性分析。结果ABI<0.9患者颈动脉粥样硬化斑块发生率为66.67%,而ABI≥0.9患者颈动脉粥样硬化斑块的发生率为21.22%,组间差异有统计学意义(P<0.05)。经Pearson相关性分析可得,2型糖尿病患者颈动脉脉粥样硬化斑块发生率与其ABI水平呈负相关(r=-0.415,P<0.05)。结论2型糖尿病患者ABI水平与其动脉粥样硬化发生率呈负相关关系,预示着ABI可在临床中作为预测动脉粥样硬化发生风险的重要指标,而二者结合可能更有益于动脉粥样硬化性心血管疾病(ASCVD)的早期筛查。

Objective To study the correlation between ankle-brachial index(ABI)and carotid atherosclerosis in patients with type 2 diabetes.Methods A random selection of 693 patients with type 2 diabetes who were treated in our outpatient clinics and wards from January 2018 to December 2020 were selected as the subjects of this study,and related clinical data such as gender,age,and course of disease were collected.Grouping with ABI=0.9 as the cutoff value:ABI<0.9 is group A,and ABI≥0.9 is group B.Check the carotid artery intima-media thickness(IMT),the presence or absence of plaque,the inner diameter of the blood vessel and other ultrasonic detection parameters of the two groups of patients.And carry out correlation analysis.Results The incidence of carotid atherosclerotic plaque in patients with ABI<0.9 was 66.67%,and the incidence of carotid atherosclerotic plaque in patients with ABI≥0.9 was 21.22%.There was a significant statistical difference between the two groups(P<0.05).According to Pearson correlation analysis,the incidence of carotid atherosclerotic plaque in patients with type 2 diabetes was negatively correlated with its ABI level(r=-0.415,P<0.05).Conclusion The level of ABI in type 2 diabetes patients is negatively correlated with the incidence of atherosclerosis,indicating that ABI can be used as an important indicator for predicting the risk of atherosclerosis in clinical practice,and the combination of the two may be more beneficial for atherosclerosis.Early screening for cardiovascular disease(ASCVD).